McKesson (MCK) Peer Comparison
$1,059.21
$-12.79
(-1.19%)
As on 06-Nov-2026 11:43EST
Market cap
$124,985 Mln
Revenue (TTM)
$418,790 Mln
P/E Ratio
27.7
P/B Ratio
4.9
Div. Yield
0 %
Edit
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
124,985 | 1,206,069 | 655,559 | 509,498 | 362,526 |
Revenue ($ Mln) |
418,790 | 86,462 | 99,335 | 66,014 | 67,302 |
Net Profit ($ Mln) |
4,700.00 | 27,579.70 | 16,095.00 | 10,350.00 | 2,453.00 |
Net Margin (%) |
1.12 | 31.90 | 16.20 | 15.68 | 3.64 |
RoE (%) |
-- | 77.18 | 19.78 | -- | 5.41 |
Price to Earnings |
27.65 | 43.95 | 41.32 | 49.53 | 148.42 |
Price-To-Book |
4.92 | 30.19 | 8.16 | 245.29 | 8.85 |
Income Statement ($ Mln)
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
403,430.00 | 65,179.00 | 94,193.00 | 61,160.00 | 64,926.00 |
|
Cost of Revenue
|
388,880.00 | 11,052.00 | 30,256.00 | 18,204.00 | 18,195.00 |
|
Gross Profit
|
14,550.00 | 54,127.00 | 63,937.00 | 42,956.00 | 46,731.00 |
|
Operating Expenses
|
8,096.00 | 24,431.00 | 38,341.00 | 22,865.00 | 23,245.00 |
|
Operating Profit (EBIT)
|
6,454.00 | 29,696.00 | 25,596.00 | 20,091.00 | 23,486.00 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
6,201.00 | 25,731.00 | 32,581.00 | 6,597.00 | 21,067.00 |
|
Provision for Tax
|
1,102.00 | 5,091.00 | 5,777.00 | 2,364.00 | 2,804.00 |
|
Profit after Tax (Net Income)
|
4,762.00 | 20,640.00 | 26,804.00 | 4,226.00 | 18,254.00 |
|
Minority Interest
|
1,338.00 | -- | -- | 42.00 | 56.00 |
|
Consolidated Profit
|
3,295.00 | 20,640.00 | 26,804.00 | -- | 18,254.00 |
Liabilities ($ Mln)
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-2,172.00 | 26,535.00 | 81,544.00 | -3,228.00 | 52,606.00 |
|
Minority Interest
|
1,338.00 | -- | -- | 42.00 | 56.00 |
|
Non-Current Liabilities
|
16,140.00 | 50,713.00 | 63,540.00 | 93,899.00 | 55,877.00 |
|
Current Liabilities
|
67,017.00 | 35,228.00 | 54,126.00 | 43,289.00 | 28,327.00 |
|
Total Liabilities
|
82,323.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
Assets ($ Mln)
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
25,113.00 | 56,847.00 | 143,586.00 | 104,898.00 | 93,350.00 |
|
Current Assets
|
57,210.00 | 55,629.00 | 55,624.00 | 29,062.00 | 43,516.00 |
|
Total Assets
|
82,323.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
|
Total Debt*
|
8,614.00 | 42,503.00 | 47,933.00 | 69,068.00 | 50,534.00 |
|
Net Current Assets
|
-9,807.00 | 20,401.00 | 1,498.00 | -14,227.00 | 15,189.00 |
Cashflow ($ Mln)
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
6,155.00 | 16,813.00 | 24,530.00 | 19,030.00 | 16,472.00 |
|
Cash Flow from Investing Activities
|
-3,432.00 | -10,972.00 | -23,588.00 | -6,643.00 | -13,741.00 |
|
Cash from Financing Activities
|
-4,631.00 | -2,213.00 | -5,539.00 | -12,724.00 | -1,922.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
78.46 | 35.32 | 22.56 | 6.17 | 19.45 |
|
ROE (%)
|
-246.35 | 101.36 | 35.03 | 6,214.71 | 36.91 |
|
ROA (%)
|
6.05 | 21.59 | 14.13 | 3.14 | 14.37 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
1.18 | 31.67 | 28.46 | 6.91 | 28.12 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.12 | 0.45 | 0.06 | 0.09 | 0.01 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
44.52 | 94.90 | 90.56 | -1.22 | 6.64 |
|
EPS Growth (%)
|
0.48 | 0.96 | 0.90 | -0.01 | 0.09 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
22.30 | 46.76 | 18.83 | 95.92 | 14.35 |
|
Price / Book Value
|
-48.89 | 36.37 | 6.19 | -125.57 | 4.98 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
15.44 | 31.56 | 12.97 | 26.61 | 10.54 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-3.97 | 1.60 | 0.59 | -21.40 | 0.96 |
|
Short term debt to equity ratio
|
-0.72 | 0.06 | 0.10 | -2.71 | 0.05 |
|
Current Ratio
|
0.85 | 1.58 | 1.03 | 0.67 | 1.54 |
|
Quick Ratio
|
0.49 | 1.19 | 0.77 | 0.56 | 1.30 |
|
Interest Coverage
|
26.11 | 37.34 | 34.55 | 3.28 | 16.52 |
Operating Efficiency Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
6.94 | 30.92 | 18.24 | 20.58 | 19.53 |
|
Asset Turnover
|
5.12 | 0.68 | 0.50 | 0.45 | 0.51 |
|
Receivable days
|
24.28 | 93.67 | 70.00 | 70.20 | 64.57 |
|
Inventory Days
|
22.17 | 352.51 | 160.77 | 91.61 | 128.14 |
|
Payable days
|
54.15 | 142.23 | 134.61 | 65.58 | 85.14 |
|
Cash Conversion Cycle
|
-7.70 | 303.95 | 96.16 | 96.23 | 107.57 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
